William Blair restated their outperform rating on shares of LogicBio Therapeutics (NASDAQ:LOGC) in a research note published on Friday morning, Zacks.com reports.

Several other analysts also recently commented on LOGC. Zacks Investment Research downgraded shares of LogicBio Therapeutics from a buy rating to a hold rating in a report on Thursday, November 14th. Chardan Capital reiterated a buy rating and issued a $20.00 target price on shares of LogicBio Therapeutics in a report on Friday. Finally, ValuEngine upgraded shares of LogicBio Therapeutics from a hold rating to a buy rating in a report on Tuesday, October 29th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $18.67.

LOGC opened at $7.38 on Friday. The company has a current ratio of 15.72, a quick ratio of 15.72 and a debt-to-equity ratio of 0.18. The company’s fifty day moving average price is $7.60 and its two-hundred day moving average price is $9.79. LogicBio Therapeutics has a 1-year low of $6.34 and a 1-year high of $20.07. The company has a market cap of $163.45 million, a price-to-earnings ratio of -2.43 and a beta of 0.82.

LogicBio Therapeutics (NASDAQ:LOGC) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.02). As a group, equities analysts forecast that LogicBio Therapeutics will post -1.78 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in LOGC. Charles Schwab Investment Management Inc. raised its holdings in shares of LogicBio Therapeutics by 9.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 22,484 shares of the company’s stock valued at $293,000 after purchasing an additional 1,969 shares during the last quarter. BlackRock Inc. grew its position in LogicBio Therapeutics by 23.2% during the second quarter. BlackRock Inc. now owns 451,723 shares of the company’s stock valued at $5,873,000 after buying an additional 85,079 shares during the period. Vanguard Group Inc. grew its position in LogicBio Therapeutics by 2.8% during the second quarter. Vanguard Group Inc. now owns 277,859 shares of the company’s stock valued at $3,612,000 after buying an additional 7,588 shares during the period. Finally, First Trust Advisors LP bought a new position in LogicBio Therapeutics during the third quarter valued at about $156,000. Institutional investors own 55.88% of the company’s stock.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.

Recommended Story: Buy-Side Analysts

Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.